Blood collection devices plays a crucial role in the patient treatment. For the treatment, blood samples are collected to measure the basic metabolism components such as blood urea nitrogen, sodium, potassium, creatinine, magnesium, chloride, and also used to measure blood glucose and lipid levels. In the recent years, as technology has increased in availability and complexity, the experts in the laboratories are receiving wide range of opportunities and challenges. In case of opportunity, automated method of collection enables technologists to perform a greater variety of tests on smaller sample quantities with greater accuracy of outcomes than the manual blood collection process. Therefore, there is an increasing number of laboratories taking their pace in the market from their hematology and chemistry analyzers to automated platforms.
Moreover the increasing demand for blood donations is also fuelling the demand of blood collection device market. For instance, according to World Health Organization (WHO), 112.5 million blood donations collected globally and there is an increase of 10.7 million blood donations from unpaid donors has been reported from 2008 to 2013. Furthermore, according to the American National Red Cross, around 7,000 units of platelets and 10,000 units of plasma are required daily in the U.S. and nearly 21 million blood components are transfused each year in the U.S.
Increasing prevalence of certain disease conditions such as cancer, HIV/AIDS, diabetes, coronary heart disease, and anemia are the driving factor for the growth of the blood collection devices market. In addition, increasing numbers of surgeries and high demand for blood transfusion and casualty cases are further driving the growth of blood collection devices market. According to the Centers for Disease Control and Prevention (CDC), the U.S. reported 26,203 cases of Lyme disease for the period between 2006 and 2016. According to the same source, around 10,265 deaths were reported due to alcohol-impaired crashes in 2015 which accounted for around 29% of all traffic-related deaths in the U.S.
Blood Collection Devices Market Taxonomy:
On the basis of type, blood collection devices market segmented into:
On the basis of method of collection, blood collection devices market segmented into:
On the basis of end user, blood collection devices market segmented into:
Continuous product advancement in blood collection devices fuel the growth of the market
Tasso, Inc., a company engaged in the manufacture of HemoLink, a simplified blood collection device used in the various diagnostic application received the US$ 3 million funding from Defenses Advanced Research Projects Agency (DARPA) to advances their HemoLink technology by collaborating with GenTegra LLC, a company engaged in the manufacture of product used in the biopreservation, biobanking and in vitro diagnostics. Moreover the continuous product development and future advances in the blood collection techniques are expected to propel the growth of blood collection devices market.
Recent FDA approvals to enter novel and technologically advanced blood collection devices in the market
DBS System SA- granted the USPTO patent for HemaXis Microfluidic blood collection platform in November 2017. HemaXis DB is microfluidic blood collection system, which uses the microfluidic chip with a standard filter card and protective case to provide the practical solution for blood collection procedure.
Seventh Sense Biosystems, Inc. in February 2017 received U.S. FDA clearance for its new blood collection device named Touch Activated Phlebotomy (TAP). TAP is novel blood collection device used for convenient and painless blood testing. Moreover in October 2017, Ionis Pharmaceuticals- a company engaged in the RNA-targeted drug discovery and development to develop drug for severe and orphan disease has made collaboration with Seventh Sense Biosystems to support the development of improved blood collection and diagnostic device. The collaboration enables the further product development of TAP device for blood testing.
Velano Vascular, Inc. - a medical device company manufactures the needle-free, vascular device for blood collection, received the FDA approval for its updated version of needle-free blood draw device. The Velano device is designed to reduce blood draw related anxiety and discomfort in hospital patients allowing safer work environment for healthcare professionals. The FDA approved blood collection devices with their increased acceptability helps to favor the further growth of the market.
Key players in the blood collection devices market:
Some of the key players in the blood collection devices market includes Becton, Dickinson and Company, NIPRO Medical Corporation, Terumo Medical Corporation, Medtronic plc, Qiagen, Bio-Rad Laboratories, Inc., Haemonetics Corporation, and Fresenius SE & Co. KGaA.